The objectives of this research project are to design and develop novel biodegradable macromolecular Gd(lll) complexes as safe, effective magnetic resonance imaging (MRI) blood pool contrast agents. Polydisulfide Gd(lll) complexes are non-toxic, have prolonged blood circulation time, can degrade and rapidly eliminate from the body as shown in animal models. They are promising for further preclinical and clinical development. The proposed research will focus on the optimization of the structure of polydisulfides to develop a new generation of non-ionic polydisulfide Gd(lll) complexes with controllable in vivo degradation rate and pharmacokinetics, and improved in vivo contrast enhancement. The novel non-ionic agents will have minimal tissue accumulation, low osmolality and broad applications in clinical practice.
The specific aims are to design, synthesize and characterize novel non-ionic polydisulfide Gd(lll) complexes with controllable degradation rate and controllable plasma pharmacokinetics;to study their physicochemical properties including relaxivities, degradability and the thermodynamic stability of Gd(lll) chelates and chemical stability of the macromolecular agents;to investigate the plasma pharmacokinetics, elimination and biodistribution, hemodynamic safety, acute and subacute tolerance and maximum tolerated dose of the novel agents;to investigate efficacy of the biodegradable macromolecular contrast agents in tumor imaging in animal models with conventional and dynamic contrast enhanced MRI;and to identify a lead agent with controllable degradation rate, effective contrast enhancement, minimal body retention and optimal safety profiles for further preclinical and clinical development. The long-term goal of this project is to develop a safe, effective biodegradable macromolecular blood pool MRI contrast agent for clinical applications in cancer imaging. This research project is proposed to develop more effective MRI contrast agents to improve accuracy for the earlier diagnosis of life-threatening diseases including cancer and diseases in the cardiovascular systems. Earlier detection and diagnosis will allow the physicians caring these patients to pursue the earliest treatment of these diseases, improve the quality of the patients'life and reduce the mortality rate.

National Institute of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Research Project (R01)
Project #
Application #
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Liu, Christina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Biomedical Engineering
Schools of Engineering
United States
Zip Code
Han, Zheng; Wu, Xiaohui; Roelle, Sarah et al. (2017) Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer. Nat Commun 8:692
Zhou, Zhuxian; Han, Zhen; Lu, Zheng-Rong (2016) A targeted nanoglobular contrast agent from host-guest self-assembly for MR cancer molecular imaging. Biomaterials 85:168-79
Ye, Zhen; Zhou, Zhuxian; Ayat, Nadia et al. (2016) A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent. Contrast Media Mol Imaging 11:32-40
Gujrati, Maneesh; Vaidya, Amita M; Mack, Margaret et al. (2016) Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy. Adv Healthc Mater 5:2882-2895
Malamas, Anthony S; Jin, Erlei; Gujrati, Maneesh et al. (2016) Dynamic Contrast Enhanced MRI Assessing the Antiangiogenic Effect of Silencing HIF-1? with Targeted Multifunctional ECO/siRNA Nanoparticles. Mol Pharm 13:2497-506
Gujrati, Maneesh; Vaidya, Amita; Lu, Zheng-Rong (2016) Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery. Bioconjug Chem 27:19-35
Parvani, Jenny G; Gujrati, Maneesh D; Mack, Margaret A et al. (2015) Silencing ?3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Res 75:2316-2325
Malamas, Anthony S; Jin, Erlei; Zhang, Qi et al. (2015) Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model. Pharm Res 32:3029-43
Zhou, Zhuxian; Mondjinou, Yawo; Hyun, Seok-Hee et al. (2015) Gd3+-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic-2-hydroxypropyl-?-cyclodextrin/Pluronic Polyrotaxane as a Long Circulating High Relaxivity MRI Contrast Agent. ACS Appl Mater Interfaces 7:22272-6
Zhou, Zhuxian; Qutaish, Mohammed; Han, Zheng et al. (2015) MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent. Nat Commun 6:7984

Showing the most recent 10 out of 42 publications